YIYan A. Ivanenkov

Yan A. Ivanenkov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan A. Ivanenkov has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enhancing accuracy of virtual kinase profiling via application of graph neural network to 3D pharmacophore ensembles

    by Alexey Ereshchenko, Sergei Evteev, Alexander Malyshev, Denis Adjugim, Fedor Sizov, Anna Pastukhova, Victor Terentiev, Petr Shegai, Andrey Kaprin, Yan Ivanenkov

    Kinase profiling is an essential step in both hit identification and selectivity evaluation. Since in vitro testing of large chemical libraries is costly and time-consuming, a computational approach can be applied to narrow down the reasonable chemical space. In this work, we collected data from several sources and prepared a curated, comprehensive database for training machine learning (ML) models to predict selectivity towards 75 kinases. We demonstrated the usefulness of this database by preparing several ML models with various molecular representations and model architectures. Among these, a graph neural network-based model enhanced by utilizing 3D pharmacophore ensembles showed the best performance. Finally, the developed model was applied to a library of in-stock compounds to facilitate kinase-focused drug discovery. Graphical abstract


  • Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)

    by Yan A. Ivanenkov, Alexander S. Malyshev, Victor A. Terentiev, Anastasia A. Korzhenevskaya, Sergei A. Evteev, Sergey Z. Vatsadze, Aleksei V. Medved’kO, Petr V. Shegai, Andrey D. Kaprin

    IntroductionThe ataxia telangiectasia mutated kinase (ATM) is key in coordinating the DDR signaling network essential for responding to double-strand breaks (DSBs). Several ATM inhibitors are being investigated for potential anticancer treatment in clinical trials.Areas coveredThis review aims to provide a comprehensive overview of patents and patent applications since 2003, with a particular focus on the structural properties, activity and efficacy of the claimed ATM kinase small-molecule inhibitors. The search was conducted using SciFinder, Cortellis Drug Discovery Intelligence Database, and Espacenet. After filtering, 44 records were identified for further analysis. This paper also discusses the recent progress in the clinical trials and development history.Expert opinionATM kinase is a promising target for cancer therapy. Small-molecule ATM kinase inhibitors hold significant potential in cancer treatment by enhancing the efficacy of existing DNA-damaging therapies. Patent analysis revealed that the majority of these compounds contain imidazo[4,5-c]quinolinone scaffold or its bioisosteric variations which are optimal in terms of good ATM inhibitory activity and selectivity over closely related enzymes. Clinical trials explore combinations with RT or DNA-targeted compounds like PARP inhibitors, which induce DSBs. The medicinal chemistry field anticipates that these therapeutic options will soon be available on the pharmaceutical market.


  • Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

    by Vladimir Aladinskiy, Chris Kruse, Luoheng Qin, Eugene Babin, Yaya Fan, Georgiy Andreev, Heng Zhao, Yanyun Fu, Man Zhang, Yan Ivanenkov, et al.

    Traf2- and Nck-interacting kinase (TNIK) has been identified as a promising therapeutic target for the treatment of fibrosis-driven diseases. Utilizing a structure-based drug design workflow, we developed a series of potent TNIK inhibitors that modulate the conformation of the gatekeeper Met105 side chain and access the TNIK back pocket. The lead optimization efforts culminated in the discovery of the recently reported compound 4 (INS018_055), a novel TNIK inhibitor. This molecule demonstrated excellent activity in both enzymatic and cell-based assays, along with high selectivity in a kinome panel. Further, in vitro and in vivo preclinical studies revealed favorable in vitro and in vivo DMPK properties. Results from multiple cell-based and animal models proved that compound 4 exhibits considerable antifibrotic and anti-inflammatory efficacy. Currently, phase II clinical trials of compound 4 are underway for the treatment of idiopathic pulmonary fibrosis (IPF).


  • AlphaFold for a medicinal chemist: tool or toy?

    by Ya. A. Ivanenkov, S. A. Evteev, A. S. Malyshev, V. A. Terentiev, D. S. Bezrukov, A. V. Ereshchenko, A. A. Korzhenevskaya, B. A. Zagribelnyy, P. V. Shegai, A. D. Kaprin

    The development of novel small drug molecules is a complex and important cross-disciplinary task. In the early stages of development, chemoinformatics and bioinformatics methods are routinely used to reduce the cost of finding a lead compound. Among the tools of medicinal chemistry, docking and molecular dynamics occupy a special place. These methods are used to predict the possible mechanism of binding of a potential ligand to a protein target. However, in order to perform a docking study, it is necessary to know the spatial structure of the protein under investigation. Although databases of crystallographic structures are available, the three-dimensional representations of many protein molecules have not been reported. There is therefore a need to model such three-dimensional conformations. Several computer algorithms have been published to solve this problem. AlphaFold is considered by the scientific community to be the most effective approach to predicting the three-dimensional structure of proteins. However, the scope of its application in medicinal chemistry, especially for virtual screening, remains unclear. This review describes methods for predicting the three-dimensional structure of a protein and provides representative examples of the use of AlphaFold for the design and rational selection of potential ligands. Special attention is given to publications presenting the results of experimental validation of the approach. On the basis of performed analysis, the main problems in the field and possible ways to solve them are formulated. The bibliography includes 154 references.


  • Open Access

    The Hitchhiker’s Guide to Deep Learning Driven Generative Chemistry

    by Yan Ivanenkov, Bogdan Zagribelnyy, Alex Malyshev, Sergei Evteev, Victor Terentiev, Petrina Kamya, Dmitry Bezrukov, Alex Aliper, Feng Ren, Alex Zhavoronkov

    This microperspective covers the most recent research outcomes of artificial intelligence (AI) generated molecular structures from the point of view of the medicinal chemist. The main focus is on studies that include synthesis and experimental in vitro validation in biochemical assays of the generated molecular structures, where we analyze the reported structures' relevance in modern medicinal chemistry and their novelty. The authors believe that this review would be appreciated by medicinal chemistry and AI-driven drug design (AIDD) communities and can be adopted as a comprehensive approach for qualifying different research outcomes in AIDD.


  • Top Cited Papers
    Open Access

    Chemistry42: An AI-Driven Platform for Molecular Design and Optimization

    by Yan A. Ivanenkov, Daniil Polykovskiy, Dmitry Bezrukov, Bogdan Zagribelnyy, Vladimir Aladinskiy, Petrina Kamya, Alex Aliper, Feng Ren, Alex Zhavoronkov

    Chemistry42 is a software platform for de novo small molecule design and optimization that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methodologies. Chemistry42 efficiently generates novel molecular structures with optimized properties validated in both in vitro and in vivo studies and is available through licensing or collaboration. Chemistry42 is the core component of Insilico Medicine's Pharma.ai drug discovery suite. Pharma.ai also includes PandaOmics for target discovery and multiomics data analysis, and inClinico─a data-driven multimodal forecast of a clinical trial's probability of success (PoS). In this paper, we demonstrate how the platform can be used to efficiently find novel molecular structures against DDR1 and CDK20.


  • Antibacterial activity of noscapine analogs

    by Yan A. Ivanenkov, Kseniya Yu. Filyaeva, Rustam T. Matniyazov, Andrey Kh. Baymiev, Alexey Kh. Baymiev, Anastasiya A. Vladimirova, Renat S. Yamidanov, Ayrat R. Mavzyutov, Zulfia R. Zileeva, Liana F. Zainullina, et al.


  • Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them

    by Aleksei E. Machulkin, Radik R. Shafikov, Anastasia A. Uspenskaya, Stanislav A. Petrov, Anton P. Ber, Dmitry A. Skvortsov, Ekaterina A. Nimenko, Nikolay U. Zyk, Galina B. Smirnova, Vadim S. Pokrovsky, et al.

    Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a suitable target for specific delivery of antitumor drugs and diagnostic agents due to its overexpression in prostate cancer cells. In the current work, we describe the design, synthesis, and biological evaluation of novel low-molecular PSMA ligands and conjugates with fluorescent dyes FAM-5, SulfoCy5, and SulfoCy7. In vitro evaluation of synthesized PSMA ligands on the activity of PSMA shows that the addition of aromatic amino acids into a linker structure leads to a significant increase in inhibition. The conjugates of the most potent ligand with FAM-5 as well as SulfoCy5 demonstrated high affinities to PSMA-expressing tumor cells in vitro. In vivo biodistribution in 22Rv1 xenografts in Balb/c nude mice of PSMA-SulfoCy5 and PSMA-SulfoCy7 conjugates with a novel PSMA ligand demonstrated good visualization of PSMA-expressing tumors. Also, the conjugate PSMA-SulfoCy7 demonstrated the absence of any explicit toxicity up to 87.9 mg/kg.


  • Discovery of Bivalent GalNAc-Conjugated Betulin as a Potent ASGPR-Directed Agent against Hepatocellular Carcinoma

    by Emil Yu. Yamansarov, Elena V. Lopatukhina, Sergei A. Evteev, Dmitry A. Skvortsov, Anton V. Lopukhov, Sergey V. Kovalev, Alexander N. Vaneev, Dmitry O. Shkil’, Roman A. Akasov, Alexander N. Lobov, et al.

    Herein, we describe the design, synthesis, and biological evaluation of novel betulin and N-acetyl-d-galactosamine (GalNAc) glycoconjugates and suggest them as targeted agents against hepatocellular carcinoma. We prepared six conjugates derived via the C-3 and C-28 positions of betulin with one or two saccharide ligands. These molecules demonstrate high affinity to the asialoglycoprotein receptor (ASGPR) of hepatocytes assessed by in silico modeling and surface plasmon resonance tests. Cytotoxicity studies in vitro revealed a bivalent conjugate with moderate activity, selectivity of action, and cytostatic properties against hepatocellular carcinoma cells HepG2. An additional investigation confirmed the specific engagement with HepG2 cells by the enhanced generation of reactive oxygen species. Stability tests demonstrated its lability to acidic media and to intracellular enzymes. Therefore, the selected bivalent conjugate represents a new potential agent targeted against hepatocellular carcinoma. Further extensive studies of the cellular uptake in vitro and the real-time microdistribution in the murine liver in vivo for fluorescent dye-labeled analogue showed its selective internalization into hepatocytes due to the presence of GalNAc ligand in comparison with reference compounds. The betulin and GalNAc glycoconjugates can therefore be considered as a new strategy for developing therapeutic agents based on natural triterpenoids.


  • New Small-Molecule Glycoconjugates of Docetaxel and GalNAc for Targeted Delivery to Hepatocellular Carcinoma

    by Rostislav A. Petrov, Sofiia R. Mefedova, Emil Yu. Yamansarov, Svetlana Yu. Maklakova, Dmitrii A. Grishin, Elena V. Lopatukhina, Olga Y. Burenina, Anton V. Lopukhov, Sergey V. Kovalev, Yury V. Timchenko, et al.

    In this work, we have developed covalent and low molecular weight docetaxel delivery systems based on conjugation with N-acetyl-d-galactosamine and studied their properties related to hepatocellular carcinoma cells. The resulting glycoconjugates have an excellent affinity to the asialoglycoprotein receptor (ASGPR) in the nanomolar range of concentrations and a high cytotoxicity level comparable to docetaxel. Likewise, we observed the 21–75-fold increase in water solubility in comparison with parent docetaxel and prodrug lability to intracellular conditions with half-life values from 25.5 to 42 h. We also found that the trivalent conjugate possessed selective toxicity against hepatoma cells vs control cell lines (20–35 times). The absence of such selectivity in the case of monovalent conjugates indicates the effect of ligand valency. Specific ASGPR-mediated cellular uptake of conjugates was proved in vitro using fluorescent-labeled analogues. In addition, we showed an enhanced generation of reactive oxygen species in the HepG2 cells, which could be inhibited by the natural ligand of ASGPR. Overall, the obtained results highlight the potential of ASGPR-directed cytostatic taxane drugs for selective therapy of hepatocellular carcinoma.